Additionally, Judge Marston has scheduled an evidentiary hearing for May 20, 2025, to address early discovery and motions on issues including preemption, warning labels, and gastroparesis diagnostic testing standards
Compounded semaglutide is not an FDA-approved finished product, and the agency does not review compounded preparations for safety, effectiveness or quality before they are marketed
None of these topical formulations are FDA-approved, which means the agency has not evaluated their safety, efficacy, or quality prior to marketing
Additionally, our study looked at other contributors of retained gastric contents on EGD
The FDAs own guidance is that patients should obtain a prescription from their doctor and fill it at a state-licensed pharmacy, and that a licensed doctor should be available to answer questions after you receive your medication
Patient Counseling Patients should be told to inform their surgical, anesthesia, dental, endoscopy, and procedural teams if they use GLP-1 or dual incretin medications
